Hemagglutinin protein of Avian Influenza Virus type A subtype H9N2 (HA (H9N2))

The hemagglutinin protein of Avian Influenza Virus type A subtype H9N2 is a viral surface glycoprotein crucial for virus entry, mediating attachment to sialic acid-containing receptors on host cell membranes and subsequent membrane fusion. It is the major antigenic determinant of the virus and the principal target for host neutralizing antibodies and vaccines. H9N2 HA exhibits considerable antigenic and genetic diversity due to frequent mutations, some of which alter receptor specificity (from avian α2,3-linked to human α2,6-linked sialic acids), facilitating cross-species transmission and contributing to pandemic potential. It is intensely studied both as a model for influenza host adaptation and as a vaccine antigen for controlling avian influenza outbreaks and mitigating human infection risk. Key antigenic and functional features include: multiple antigenic sites exist close to the receptor binding domain; monoclonal antibodies have mapped at least 5 distinct epitopes with ongoing antigenic drift. Cleavage site sequence (e.g., RSSR, PSRSSR/G) in HA influences infectivity, replication and species tropism; tribasic motifs are linked to increased pathogenicity in birds and mammals. Key mutations such as Q226L, D145G/N, and N193E shift receptor binding preference and can enhance transmission or facilitate human adaptation. HA elicits strong immunogenicity and is the basis for commonly used HI tests and recombinant vaccines. Clinical and therapeutic relevance: HA is not directly targeted by classic antiviral drugs but is the focus of monoclonal antibody therapies and vaccine design. Sequence variation in HA informs surveillance for drug resistance, vaccine updates, and risk of zoonotic transmission. Notable research highlights: HA antigenic structure is mapped in detail using monoclonal antibodies, revealing multiple non-overlapping antigenic sites adjacent to the receptor-binding site. Recombinant H9N2 HA is a potent immunogen with thermal and acid stability, inducing strong antibody and cytokine responses in experimental vaccines. The receptor-binding domain undergoes key substitutions (Q226L, N193E, D145G/N, etc.), enabling binding to both avian and human-like receptors and broadening host range.

Other names

H9N2 hemagglutininH9N2 HAAvian Influenza A H9N2 hemagglutininInfluenza virus hemagglutinin (H9N2 subtype)

Blockade of receptor binding and fusion by neutralizing antibodies (e.g., vaccine-induced or therapeutic mAbs). Prevention of virus entry into host cells (antibody-mediated and vaccine-induced immunity).